Bart D Maes

Abstract Albuminuria is a central biomarker in chronic kidney disease (CKD), used for the detection and prognosis of the disease. In clinical trials assessing CKD progression, change in the level of albuminuria is a candidate surrogate endpoint for kidney failure. Evaluation of the validity of this surrogate endpoint across a diverse range of interventions and populations is required to support its further acceptance.

Get full access to this article View all access and purchase options for this article. References Abou-Chadi T. 2018. “Electoral competition, Political Risks, and Parties’ Responsiveness to Voters’ Issue Priorities.” Electoral Studies 55: 99–108. Baekgaard M., Christensen J., Dahlmann C., Mathiasen A., Petersen N. 2019. “The Role of Evidence in Politics: Motivated Reasoning and Persuasion Among Politicians.” British Journal of Political Science 49: 1117–1140. Ban P., Park J., You H.

A 67-year-old woman was referred to our department for investigation of a 3-year history of declining renal function—serum creatinine concentration was 1·2 mg/dL (typical range 0·51–0·95) and the estimated glomerular filtration rate was 47 mL/min per 1·73 m2 (typical range >60). The patient had also been found to have persistent painless microscopic haematuria and a urinary albumin-to-creatinine ratio of up to 235 mg/g (typical range <30). She also reported mild muscle pains in her arms and legs.